1.Fluoropyrimidines S-1 and Capecitabine may Prolong International Normalized Ratios of Prothrombin Time by 3-Fold in Cancer Patients Receiving Warfarin
Masayuki Ikenishi ; Akiko Kuroda ; Haruhiko Tsukazaki ; Masahiko Nakao ; Masashi Takeuchi ; Yuji Konishi ; Toshiyuki Matsuda ; Tohru Ohtori ; Kenji Matsuyama ; Mitsutaka Takada ; Hiroki Satoh ; Yasufumi Sawada ; Mutsuaki Ueda
Japanese Journal of Drug Informatics 2016;18(3):172-178
Objective: To compare effects of the fluoropyrimidines S-1 and capecitabine on prothrombin time international normalized ratios (PT-INR) of warfarin following coadministration and after discontinuation of each fluoropyrimidine treatment.
Methods: Medical records of patients receiving warfarin with either S-1 (6 patients) or capecitabine (7 patients) were obtained from four hospitals.
Results: Increased PT-INR was observed until peak levels of warfarin were achieved in all patients in S-1 and capecitabine treatment groups. Moreover, PT-INR significantly changed after coadministration within each group (p<0.05). Specifically, ratios of peak PT-INR after coadministration of each fluoropyrimidine and those following administration of warfarin alone (PT-INR elevation ratio) were 3.31 and 3.29 in S-1 and capecitabine coadministration groups, respectively. Moreover, numbers of days to peak PT-INR were 38.3 and 31.3 days, respectively, and did not significantly differ between the treatment groups. Furthermore, PT-INR returned to pretreatment levels by 17.5 and 15.1 days after discontinuation of S-1 and capecitabine, respectively, and did not significantly differ between the treatment groups.
Conclusion: Coadministration of S-1 and capecitabine similarly prolongs PT-INR by approximately 3-fold compared with administration of warfarin alone; therefore, these drug-drug interactions were clinically suggested to be of high risk for episodes of bleeding and remarkable alterations in coagulation parameters. Therefore, blood coagulation ability should be more carefully monitored with regard to PT-INRs in patients receiving warfarin with S-1 or capecitabine not only during coadministration but also after discontinuation of fluoropyrimidine treatments.
2.A Report on an Annual Kampo Medicine Conference Held by Medical Students in the Hokkaido and Tohoku Areas
Shohei OKADA ; Fumiya OMATA ; Takafumi TOGASHI ; Takahisa OKUDA ; Tesshin MIYAMOTO ; Miho OOSUGA ; Kohei TANAKA ; Mami ISHIYAMA ; Aiseio AISO ; Hiromichi YASUI ; Minoru YAEGASHI ; Kahori KUBO ; Soichiro KANEKO ; Tetsuharu KAMIYA ; Natsumi SAITO ; Ryutaro ARITA ; Hidekazu WATANABE ; Hitoshi NISHIKAWA ; Yuka IKENO ; Junichi TANAKA ; Minoru OHSAWA ; Akiko KIKUCHI ; Takehiro NUMATA ; Hitoshi KURODA ; Michiaki ABE ; Shin TAKAYAMA ; Tadashi ISHII
Kampo Medicine 2017;68(1):72-78
Since students who would like to study Kampo medicine more have no opportunity to communicate each other in Northern Japanese Universities, we newly started joint study conferences held by medical students in 2013. The objectives of this paper are to report on these annually held student-based Kampo study conferences in the Hokkaido and Tohoku areas, and the ways each university studies Kampo medicine. In the conference, the students reported on their club activities. Then they studied the history of Kampo medicine and simulation of abdominal diagnosis, and performed group work on case reports together. The number of student participants in these conferences has tripled over 3 years from 18 to 58 (for a total of 111 participants). All members were satisfied with the content. And this reflects medical students' need for a wider perception of Kampo medicine, rather than a limited one gained in their university club activities. We hope this conference will play a major role in other nationwide student-based Kampo study conferences in the years to come.
3.Autologous Blood Donation for Patients With Low-Lying Placenta
Heisuke HIROWATARI ; Shigeru TODA ; Mai FUJIKURA ; Keita KURODA ; Mayuko BANDO ; Komei KATAYAMA ; Maya HANATANI ; Takuto NAKAMURA ; Aya SOBAJIMA ; Hiromi FUJIKI ; Akiko FUKATSU ; Takayasu SUGANUMA ; Takahiro SUZUKI
Journal of the Japanese Association of Rural Medicine 2021;70(4):354-359
This study was undertaken to elucidate the usefulness and problems of autologous blooddonation for the patients with low-lying placenta. Seventy-eight women with low-lying placentawho gave birth in our institution were retrospectively analyzed. Autologous blood donation wasperformed in 58 patients (74%). The median volume of donated blood was 300 mL. Patients withor without autologous blood donation showed no significant difference in the distance betweenthe edge of the placenta and the internal os of the uterus. Median blood loss due to intrapartumhemorrhage was 1183 mL. All 7 patients with blood loss of more than 2000 mL had donatedautologous blood. The donated blood was transfused in 9 of the 58 patients (16%) who underwentautologous blood donation. No patients underwent allogenic blood transfusion. Althoughautologous blood donation was expected to be useful for avoiding allogenic blood transfusion inthese patients with low-lying placenta, the high discard rate suggests the need for a strategy toselect those patients at high risk for blood loss requiring transfusion.